Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Exits Dispatch

The relabeller trading as Vantris Bio closes after 4 years

A proper account of an operation that existed, and of what closing it cost.

the relabeller trading as Vantris Bio has ceased trading after 4 years, ending an operation that at its largest employed a few dozen people and served, on its own account, several thousand patients a month. The closure follows the resolution of the shortage listing on which a substantial share of its volume depended, and was announced to customers by email with 18 days’ notice.

At its peak the operation ran two sterile suites, held a state licence in 4 jurisdictions, and published a catalogue of preparations that ran to several dozen items. Staff were given 18 days’ notice. The Journal has spoken to three former employees, none of whom would be quoted by name while severance discussions continued.

Customer deposits held in a general operating account are the recurring feature of these administrations. It is lawful in most jurisdictions and it means that in a failure the customer is financing the wind-down. Readers who prepay should understand which of those they are doing.

"I had four weeks to move people who had been stable for a year," said Rowena Ashcombe, community pharmacist and diabetes educator. "Two of them are not on anything now."

"If your deposit is in their operating account you are an unsecured creditor," said Alastair Renshaw, pharmaceutical supply-chain consultant. "That is a lending decision most customers do not know they are making."

The Journal has asked the administrators what will happen to the batch records and will publish the answer. Former employees who wish to speak to us can reach the standards desk; we do not publish names without consent.

Note

the relabeller trading as Vantris Bio is not connected with any of the suppliers profiled in the Journal’s vendor dossiers.

Related coverage